Mu-opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic-pituitary-adrenal axis adrenocorticotropic hormone stress response to metyrapone

Addiction Biology

Volumn 18, Issue 2, 2013, Pages 325-331

  Ducat, Elizabeth ^a   Ray, Brenda ^a   Bart, Gavin ^b   Umemura, Yoshie ^a   Varon, Jack ^a   Ho, Ann ^a   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

ACTH; genetics; HPA axis; metyrapone; mu opioid receptor; OPRM1

Indexed keywords

ANTACID AGENT; CORTICOTROPIN; GLUCOCORTICOID; METYRAPONE; MU OPIATE RECEPTOR;

ADRENAL CORTEX; ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; STEROIDOGENESIS; STRESS; VOLUNTEER;

ADRENOCORTICOTROPIC HORMONE; ALLELES; ANALYSIS OF VARIANCE; ANTIMETABOLITES; AREA UNDER CURVE; EXONS; FEMALE; GENOTYPE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; METYRAPONE; PITUITARY-ADRENAL SYSTEM; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; SEX FACTORS; STRESS, PHYSIOLOGICAL; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 84874429759     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2011.00313.x     Document Type: Article

References (40)

1. Anton R, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D, (2008) An evaluation of μ-opioid receptor (OPRM) as a predictor of naltrexone response in the treatment of alcohol dependence. Arch Gen Psychiatry 65: 135-144.
2. Bart G, Heilig M, LaForge KS, Pollak L, Leal S, Ott J, Kreek MJ, (2004) Substantial attributable risk relative to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol Psychiatry 9: 547-549.
3. Bart G, Kreek MJ, Ott J, LaForge KS, Proudnikov D, Pollak L, Heilig M, (2005) Increased attributable risk related to a functional μ-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 30: 417-422. (Pubitemid 40129493)
4. Bart G, LaForge KS, Borg L, Lilly C, Ho A, Kreak MJ, (2006) Altered levels of basal cortisol in healthy subjects with a 118G allele in exon 1 of the mu opioid receptor gene. Neuropsychopharmacology 31: 2313-2317. (Pubitemid 44413212)
5. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L, (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95: 9608-9613. (Pubitemid 28506279)
6. Chong R, Oswald L, Yang X, Uhart M, Lin P, Wand G, (2006) The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacology 31: 204-211. (Pubitemid 43250957)
7. Chrousos GP, (2009) Stress and disorders of the stress system. Nat Rev Endocinol 5: 374-381.
8. Culpepper-Morgan JA, Kreek MJ, (1997) Hypothalamic-pituitary-adrenal axis hypersensitivity to naloxone in opioid dependence: a case of naloxone-induced withdrawal. Metabolism 46: 130-134. (Pubitemid 27078754)
9. Cushman P, Kreek MJ, (1974) Some endocrinologic observations in narcotic addicts. In:, Zimmerman E, George R, eds. Narcotics and the Hypothalamus, pp. 161-173. New York: Raven Press.
10. Hernandez-Avila C, Covault J, Wand G, Zhang H, Gelernter J, Kranzler H, (2007) Population-specific effects of the Asn40Asp polymorphism at the mu-opiod receptor gene (OPRM1) on HPA-axis activation. Pharmacogenet Genomics 17: 1031-1038. (Pubitemid 351339487)
11. Hernandez-Avila C, Wand G, Luo X, Gelernter J, Kranzler H, (2003) Association between the cortisol response to opioid blockade and the Asn40Asp Polymorphism at the μ-opioid receptor locus (OPRM1). Am J Med Genet B Neuropsychiatr Genet 118: 60-65. (Pubitemid 37064077)
12. Kakko J, Wachenfeldt J, Svanborg K, Lidstrom J, Barr C, Heilig M, (2008) Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence. Biol Psychiatry 63: 172-177. (Pubitemid 350299330)
13. Kapur S, Sharad S, Singh R, Gupta A, (2007) A118G polymorphism in mu-opioid receptor gene (OPRM1): association with opiate addiction in subjects of Indian origin. J Integr Neurosci 6: 511-522.
14. Kosten T, Morgan C, Kreek MJ, (1992) Beta endorphin levels during heroin, methadone, buprenorphine, and naloxone challenges: preliminary findings. Neuropsychopharmacology 32: 523-528.
15. Kreek MJ, (1973) Medical safety and side effects of methadone in tolerant individuals. JAMA 223: 665-668.
16. Kreek MJ, (1992) Rationale for maintenance pharmacotherapy of opiate dependence. In:, O'Brien CP, Jaffe JH, eds. Addictive States. Association of Research in Nervous and Mental Disease, Vol. 70, pp. 205-230. New York: Raven Press.
17. Kreek MJ, (2007) Role of a functional human gene polymorphism in stress responsivity and addictions. Clin Pharm Ther 83: 615-618.
18. Kreek MJ, LaForge KS, (2007) Stress responsivity, addiction and a functional variant of the human mu-opioid receptor gene. Mol Inter 7: 74-78.
19. Kreek MJ, Ragunath J, Plevy S, Hamer D, Schneider B, Hartman N, (1984) ACTH, cortisol and β-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides 5: 277-278. (Pubitemid 15163382)
20. Kroslak T, LaForge KS, Gianotti R, Ho A, Nielsen D, Kreek MJ, (2007) The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem 103: 77-87. (Pubitemid 47404205)
21. LaForge KS, Yuferov V, Kreek MJ, (2000) Opioid receptor and peptide gene polymorphisms: potential Implications for addictions. Eur J Pharmacol 410: 249-268. (Pubitemid 32008148)
22. Mantsch JR, Schlussman SD, Ho A, Kreek MJ, (2000) Effects of cocaine self-administration on plasma corticosterone and prolactin in rats. J Pharmacol Exp Ther 294: 239-247. (Pubitemid 30434693)
23. Nishizawa D, Han W, Hasegawa J, Ishida T, Numata Y, Sato T, Kawai A, Ikeda K, (2006) Association of mu-opioid receptor gene polymorphism A118G with alcohol dependence in a Japanese population. Neuropsychobiology 53: 137-141. (Pubitemid 43854172)
24. O'Malley S, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ, (2002) Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitray- adernocortical axis. Psychopharmacology 160: 19-29. (Pubitemid 34169822)
25. Oslin D, Berrettini W, Kranzler H, Pettinati H, Gelernter J, Volpicelli J, O'Brien C, (2003) A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28: 1546-1552. (Pubitemid 41070891)
26. Pratt W, Davidson D, (2009) Role of the HPA axis and the A118G polymorphism of the μ-opioid receptor in stress-induced drinking behavior. Alcohol Alcohol 44: 358-365.
27. Ray LA, Hutchinson KE, Ashenhurst JR, Morrow AL, (2010) Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the asp40 allele of the OPRM1 gene: a pilot investigation. Alcohol Clin Exp Res 34: 1479-1487.
28. Schluger JH, Borg L, Ho A, Kreek MJ, (2001) Altered HPA axis responsivity to metyrapone testing in methadone maintained former heroin addicts with ongoing cocaine addiction. Neuropsychopharmacology 24: 568-575. (Pubitemid 32244317)
29. Schluger JH, Ho A, Borg L, Porter M, Maniar S, Gunduz M, Perret G, King A, Kreek MJ, (1998) Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Alcohol Clin Exp Res 22: 1430-1436. (Pubitemid 28481934)
30. Szeto CT, Tang NL, Lee DT, Stadlin A, (2001) Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts. Neuroreport 12: 1103-1106. (Pubitemid 32374725)
31. Uhart M, Chong R, Oswald L, Lin P, Wand G, (2006) Gender differences in hypothalamic-pituitray-adrenal (HPA) axis reactivity. Psychoneuroendocrinology 31: 642-652.
32. Volavka J, (1980) Short-term hormonal effects of naloxone in man. Psychoneuroendocrinology 5: 225-234. (Pubitemid 10039546)
33. Volavka J, Cho D, Mallya A, Bauman J, (1979) Naloxone increases ACTH and cortisol in man. N Engl J Med 300: 1056-1057. (Pubitemid 9193267)
34. Wand G, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S, Ali A, (2002) The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26: 106-114. (Pubitemid 34075281)
35. Weitzman ED, Fukushima D, Nogeire C, Roffwarg H, Gallagher TF, Hellman L, (1971) Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J Clin Endocrin Metab 33: 14-22.
36. Young E, Ribeiro S, (2006) Sex differences in the ACTH response to 24 h metyrapone in depression. Brain Res 1126: 148-155. (Pubitemid 44880918)
37. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W, (2005) Allelic expression inbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J BiolChem 280: 32618-32624. (Pubitemid 41368304)
38. Zhou Y, Franck J, Spangler R, Maggos CE, Ho A, Kreek MJ, (2000) Reduced hypothalamic POMC and anterior pituitary CRF-1 receptor mRNA levels after acute, but not chronic, daily binge intragastric alcohol administration. Alcohol Clin Exp Res 24: 1575-1582.
39. Zhou Y, Proudnikov D, Yuferov V, Kreek MJ, (2010) Drug-induced and genetic alterations in stress-responsive systems: implications for specific addictive diseases. Brain Res 1314: 235-252.
40. Zhou Y, Spangler R, LaForge KS, Maggos CE, Ho A, Kreek MJ, (1996) Corticotropin-releasing factor and Type 1 cortiocotropin-releasing factor receptor messenger RNAs in rat brain and pituitary during 'binge'-pattern cocaine administration and chronic withdrawal. J Pharmacol Exp Ther 279: 351-358.